Price to Earnings (P/E)
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to common stockholders1 (in millions) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2019 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Moderna Inc. Annual Report.
- Share Price Trend
- The share price demonstrated a significant upward trajectory from March 2019 through February 2021, rising from $19.97 to a peak of $154.81. This growth was followed by a slight decline to $151.33 in February 2022 and then a gradual decrease to $139.26 by February 2023. By February 2024, the share price had decreased further to $96.46. The overall pattern indicates strong initial market confidence followed by a notable correction in the subsequent two years.
- Earnings Per Share (EPS) Analysis
- EPS values were negative from March 2019 through February 2021, with a downward trend reaching its lowest at -$1.87 in February 2021. A dramatic positive shift occurred in February 2022 when EPS sharply turned positive to $30.29. This positive trend declined to $21.64 in February 2023 and subsequently reversed into a negative figure of -$12.34 in February 2024. The EPS data suggests a volatile earnings performance with a temporary period of strong profitability followed by a significant downturn.
- Price-to-Earnings (P/E) Ratio Evaluation
- P/E ratios are available only for February 2022 and February 2023, standing at 5 and 6.43 respectively. These low P/E values relative to typical market standards could reflect the company’s earnings situation during those years, consistent with the strong positive EPS followed by a decline. The absence of P/E data for other periods likely correlates with negative EPS values in those years, where the ratio is not typically calculated or reported.
- Overall Financial Insights
- The data illustrates a period marked by significant fluctuations in both market valuation and profitability. Initial losses were succeeded by a strong earnings recovery, which positively influenced the share price and P/E ratios temporarily. However, the subsequent reversal in profitability and share price points to potential challenges or market adjustments in the most recent fiscal year. The volatility in EPS and share price highlights the need for close monitoring of underlying operational and market factors driving these changes.
Comparison to Competitors
Moderna Inc., P/E, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | |||||||||||||
| Feb 24, 2023 | |||||||||||||
| Feb 25, 2022 | |||||||||||||
| Feb 26, 2021 | |||||||||||||
| Feb 27, 2020 | |||||||||||||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., P/E, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).